强生 2026年季度报告

FORM 10-Q Quarterly Report Pursuant to Section13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 29, 2026 or Transition Report Pursuant to Section13 or 15(d) of the Securities Exchange Act of 1934for the transition period fromto Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) 22-1024240 (I.R.S. EmployerIdentification No.) One Johnson & Johnson PlazaNew Brunswick, New Jersey 08933(Address of principal executive offices)Registrant’s telephone number, including area code (732)524-0400 Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirementsfor the past 90days.☑Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 ofRegulationS-T during the preceding 12months (or for such shorter period that the registrant was required to submit such files).☑Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 ofthe Exchange Act. Ifanemerginggrowthcompany,indicatedbycheckmarkiftheregistranthaselectednottousetheextendedtransition periodforcomplyingwithanyneworrevisedfinancialaccountingstandardsprovided pursuantto Section 13(a) of the ExchangeAct.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).☐Yes☑No Table of contents Item Cautionary note regarding forward-looking statements This Quarterly Report on Form 10-Q and Johnson & Johnson’s other publicly available documents contain “forward-looking statements”within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.Management andrepresentatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements.Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans,objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,”“expects,” “will,” “anticipates,” “estimates,” and other words of similar meaning in conjunction with, among other things: discussions offuture operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timingof restructuring initiatives including associated cost savings and other benefits; the Company’s strategy for growth; product developmentactivities; regulatory approvals; market position and expenditures. Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they aresubject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company’s control. Investorsshould realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company’sactual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-lookingstatements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but arenot limited to: Risks related to product development, market success and competition •Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which theCompany’s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinicaldata, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;•Challenges to the Company’s ability to secure and maintain adequate patent and other intellectual property rights for new andexisting products and technologies in the United States and other important markets;•The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products andresulting revenue and market share losses;•Increasingly aggressive and frequent challenges to the Company’s patents by competitors and others seeking to launch competinggeneric, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and otherdecision makers to such challenges, potentially resulting in loss of market exclusivity and rapid dec